MedTrace Logo

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

NCT03768479 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2018-12-11

No results posted yet for this study

Summary

This study is focused on the value of 18F-FES-PET in predicting the Fulvestrant efficacy in hormone receptor-positive breast cancer. The imaging agent involved in this study is 16α-\[18F\]-fluoro-17β-estradiol (18F-FES).

Conditions

  • Estrogen Receptor-positive Breast Cancer
  • Fulvestrant

Interventions

DEVICE

18F-FES-PET

18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant

Sponsors & Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Jin Yang · First Affiliated Hospital of Xi'an Jiaotong U

  • Jin Jin · First Affiliated Hospital of Xi'an Jiaotong U

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-05
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768479 on ClinicalTrials.gov